Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 15;13(4):2626-2634.
eCollection 2021.

A preliminary study of influences of hydroxyethyl starch combined with ulinastatin on degree of edema in newborns with capillary leak syndrome

Yunping Qu  1 , Wenyan Tang  2 , Ming Hao  3 , Xiao Chen  4
Affiliations

A preliminary study of influences of hydroxyethyl starch combined with ulinastatin on degree of edema in newborns with capillary leak syndrome

Yunping Qu et al. Am J Transl Res. .

Abstract

Objective: To analyze the efficacy of hydroxyethyl starch (HES) combined with Ulinastatin (Uti) in the treatment of newborns with capillary leak syndrome (CLS).

Methods: A total of 60 newborns with CLS admitted to four hospitals were selected as the study subjects, and were randomly divided into the control group (n = 30) and the observation group (n = 30) in accordance with the random number table. The control group was treated with HES alone, while the observation group was treated with Uti combined with HES.

Results: At 5 d after treatment, the incidence rates of systemic edema and pulmonary edema, the levels of CRP, NE, and BUN, and the duration for the improvement of systemic edema, pulmonary edema and NICU hospital stay in the control group were superior to those in the observation group, while the 24-h urine output, PaO2 and MAP levels, the levels of A, SCr, ALT, and IL-10 in the observation group were superior to those in the control group (P < 0.05). After 3 months of follow-up after treatment, the mortality rate of newborns in the observation group (13.33%) was lower than that in the control group (36.67%) (P < 0.05).

Conclusion: HES combined with Uti can effectively alleviate edema, control inflammatory levels, and improve hepatic and renal functions and neonatal survival rate of newborns with CLS.

Keywords: Newborns; capillary leak syndrome; degree of edema; hydroxyethyl starch; treatment; ulinastatin.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Improvement of symptoms. The duration for the improvement of systemic and pulmonary edema (A and B) and NICU hospital stay (C) in the observation group were shorter than those in the control group (P < 0.05). *indicates P < 0.05 for the comparison between groups.
Figure 2
Figure 2
Sign levels. There was no significant difference in the comparison of 24-h urine output (A) and the levels of PaO2 (B) and MAP (C) between the two groups (P > 0.05). At 5 d after treatment, 24-h urine output and the levels of PaO2 and MAP in the observation group were lower than those in the control group (P < 0.05). *indicates P < 0.05 for the comparison between groups.
Figure 3
Figure 3
Hepatic and renal functions. Before treatment, there was no remarkable difference in the comparison of the levels of A (A), SCr (B), ALT (C) and BUN (D) between the two groups (P > 0.05). At 5 d after treatment, the levels of A, SCr and ALT in the observation group were higher than those in the control group, while the levels of BUN in the observation group were lower than those in the control group (P < 0.05). *indicates P < 0.05 for the comparison between groups.
Figure 4
Figure 4
Inflammatory levels. Before treatment, there was no marked difference in the comparison of the levels of CRP (A), IL-10 (B) and NE (C) between the two groups (P > 0.05). At 5 d after treatment, the levels of CRP, IL-10 and NE in the observation group were higher than those in the control group (P < 0.05). *indicates P < 0.05 for the comparison between groups.
Figure 5
Figure 5
Survival curve. Hazard Ratio (Mantel-Haenszel): Ratio (and its reciprocal) O/C = 0.2870, C/O = 3.484, 95% CI of ratio O/C = 0.1024 to 0.8047, C/O = 1.243 to 9.768. Hazard Ratio (logrank): Ratio (and its reciprocal) O/C = 0.2772, C/O = 3.608, 95% CI of ratio O/C = 009981 to 0.7699, C/O = 1.299 to 10.02. O = Observation group, C = Control group.
See this image and copyright information in PMC

References

    1. Baloch NU, Bikak M, Rehman A, Rahman O. Recognition and management of idiopathic systemic capillary leak syndrome: an evidence-based review. Expert Rev Cardiovasc Ther. 2018;16:331–340. - PubMed
    1. Druey KM, Parikh SM. Idiopathic systemic capillary leak syndrome (Clarkson disease) J Allergy Clin Immunol. 2017;140:663–670. - PMC - PubMed
    1. Kulihova K, Prochazkova M, Semberova J, Janota J. Fatal primary capillary leak syndrome in a late preterm newborn. Indian J Pediatr. 2016;83:1197–1199. - PubMed
    1. Asmundsson ASE, Bjorklund AR, Fisher GA. Diagnosis of systemic capillary leak syndrome in a young child treated with intravenous immunoglobulin in the acute phase. J Pediatr Intensive Care. 2018;7:94–96. - PMC - PubMed
    1. Shaw AR, Mueller BA. Antibiotic dosing in continuous renal replacement therapy. Adv Chronic Kidney Dis. 2017;24:219–227. - PubMed

LinkOut - more resources